These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31306132)

  • 21. In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion.
    Hessen E; Kirsebom BE; Eriksson CM; Eliassen CF; Nakling AE; Bråthen G; Waterloo KK; Aarsland D; Fladby T
    J Alzheimers Dis; 2019; 67(2):715-723. PubMed ID: 30614807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF Aβ
    Rizzi L; Missiaggia L; Roriz-Cruz M
    Neuromolecular Med; 2018 Dec; 20(4):491-497. PubMed ID: 30306396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
    Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
    Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of subjective memory complaint and depressive symptoms with objective cognitive functions in prodromal Alzheimer's disease including pre-mild cognitive impairment.
    Seo EH; Kim H; Choi KY; Lee KH; Choo IH
    J Affect Disord; 2017 Aug; 217():24-28. PubMed ID: 28380342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Outcome of Patients with Amyloid-Negative Amnestic Mild Cognitive Impairment.
    Cardoso S; Silva D; Alves L; Guerreiro M; de Mendonça A
    J Alzheimers Dis; 2022; 86(2):629-640. PubMed ID: 35094995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment.
    Kim SE; Woo S; Kim SW; Chin J; Kim HJ; Lee BI; Park J; Park KW; Kang DY; Noh Y; Ye BS; Yoo HS; Lee JS; Kim Y; Kim SJ; Cho SH; Na DL; Lockhart SN; Jang H; Seo SW
    J Alzheimers Dis; 2018; 66(2):681-691. PubMed ID: 30320571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2014 Sep; 20(8):836-47. PubMed ID: 25156329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
    Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
    J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a specific memory signature associated with Aβ-PET positivity in patients with amnestic mild cognitive impairment?
    Tomadesso C; Gonneaud J; Egret S; Perrotin A; Pélerin A; de Flores R; de la Sayette V; Desgranges B; Chételat G; La Joie R
    Neurobiol Aging; 2019 May; 77():94-103. PubMed ID: 30784816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study.
    Poljak A; Crawford JD; Smythe GA; Brodaty H; Slavin MJ; Kochan NA; Trollor JN; Wen W; Mather KA; Assareh AA; Ng PC; Sachdev PS
    Curr Alzheimer Res; 2016; 13(3):243-55. PubMed ID: 26679856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment.
    Rolstad S; Berg AI; Bjerke M; Blennow K; Johansson B; Zetterberg H; Wallin A
    J Alzheimers Dis; 2011; 26(1):135-42. PubMed ID: 21593572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.
    Wolfsgruber S; Jessen F; Koppara A; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Kornhuber J; Wagner M
    Neurology; 2015 Mar; 84(12):1261-8. PubMed ID: 25716354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The hard Test Your Memory. Evaluation of a short cognitive test to detect mild Alzheimer's disease and amnestic mild cognitive impairment.
    Brown JM; Wiggins J; Dong H; Harvey R; Richardson F; Hunter K; Dawson K; Parker RA
    Int J Geriatr Psychiatry; 2014 Mar; 29(3):272-80. PubMed ID: 23929807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.